Skip to main content
Erschienen in: Journal of Gastroenterology 3/2017

13.10.2016 | Review

Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis

verfasst von: Tsuyoshi Hamada, NaNa Keum, Reiko Nishihara, Shuji Ogino

Erschienen in: Journal of Gastroenterology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Molecular pathological epidemiology (MPE) is an integrative field that utilizes molecular pathology to incorporate interpersonal heterogeneity of a disease process into epidemiology. In each individual, the development and progression of a disease are determined by a unique combination of exogenous and endogenous factors, resulting in different molecular and pathological subtypes of the disease. Based on “the unique disease principle,” the primary aim of MPE is to uncover an interactive relationship between a specific environmental exposure and disease subtypes in determining disease incidence and mortality. This MPE approach can provide etiologic and pathogenic insights, potentially contributing to precision medicine for personalized prevention and treatment. Although breast, prostate, lung, and colorectal cancers have been among the most commonly studied diseases, the MPE approach can be used to study any disease. In addition to molecular features, host immune status and microbiome profile likely affect a disease process, and thus serve as informative biomarkers. As such, further integration of several disciplines into MPE has been achieved (e.g., pharmaco-MPE, immuno-MPE, and microbial MPE), to provide novel insights into underlying etiologic mechanisms. With the advent of high-throughput sequencing technologies, available genomic and epigenomic data have expanded dramatically. The MPE approach can also provide a specific risk estimate for each disease subgroup, thereby enhancing the impact of genome-wide association studies on public health. In this article, we present recent progress of MPE, and discuss the importance of accounting for the disease heterogeneity in the era of big-data health science and precision medicine.
Literatur
1.
Zurück zum Zitat Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365–7.PubMedPubMedCentralCrossRef Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365–7.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397–411.PubMedCrossRef Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397–411.PubMedCrossRef
3.
Zurück zum Zitat Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27:602–11.PubMedCrossRef Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27:602–11.PubMedCrossRef
4.
Zurück zum Zitat Nishihara R, VanderWeele TJ, Shibuya K, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015;30:1129–35.PubMedPubMedCentralCrossRef Nishihara R, VanderWeele TJ, Shibuya K, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015;30:1129–35.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26:465–84.PubMedPubMedCentralCrossRef Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26:465–84.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621–8.PubMedPubMedCentralCrossRef Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621–8.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability–molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol. 2012;41:1072–4.PubMedPubMedCentralCrossRef Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability–molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol. 2012;41:1072–4.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33:2949–55.PubMedCrossRef Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33:2949–55.PubMedCrossRef
9.
Zurück zum Zitat Sugimura H. Susceptibility to human cancer: from the perspective of a pathologist. Pathol Int. 2016;66:359–68.PubMedCrossRef Sugimura H. Susceptibility to human cancer: from the perspective of a pathologist. Pathol Int. 2016;66:359–68.PubMedCrossRef
10.
Zurück zum Zitat Chen IC, Lee KH, Hsu YH, et al. Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase protein in colorectal cancer. Dis Markers. 2016;2016:8169724.PubMedPubMedCentral Chen IC, Lee KH, Hsu YH, et al. Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase protein in colorectal cancer. Dis Markers. 2016;2016:8169724.PubMedPubMedCentral
11.
Zurück zum Zitat Jiang MJ, Dai JJ, Gu DN, et al. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta. 2016;1866:163–76.PubMed Jiang MJ, Dai JJ, Gu DN, et al. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta. 2016;1866:163–76.PubMed
12.
Zurück zum Zitat Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016;22:3227–33.PubMedPubMedCentralCrossRef Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016;22:3227–33.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Li SK, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. Trends Mol Med. 2016;22:274–89.PubMedCrossRef Li SK, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. Trends Mol Med. 2016;22:274–89.PubMedCrossRef
14.
Zurück zum Zitat Zhou L, Wang K, Li Q, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics. 2016;13:367–81.PubMedCrossRef Zhou L, Wang K, Li Q, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics. 2016;13:367–81.PubMedCrossRef
15.
Zurück zum Zitat Aran V, Victorino AP, Thuler LC, et al. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15:195–203.PubMedCrossRef Aran V, Victorino AP, Thuler LC, et al. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15:195–203.PubMedCrossRef
16.
Zurück zum Zitat Wang S, Wu S, Meng Q, et al. FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin. Sci Rep. 2016;6:19229.PubMedPubMedCentralCrossRef Wang S, Wu S, Meng Q, et al. FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin. Sci Rep. 2016;6:19229.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Kuroiwa-Trzmielina J, Wang F, Rapkins RW, et al. SNP rs16906252C > T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. Clin Cancer Res. 2016. Kuroiwa-Trzmielina J, Wang F, Rapkins RW, et al. SNP rs16906252C > T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. Clin Cancer Res. 2016.
18.
Zurück zum Zitat Ohno T, Adachi S, Okuno M, et al. Development of a novel scoring system for predicting the risk of colorectal neoplasia: a retrospective study. PLoS ONE. 2016;11:e0157269.PubMedPubMedCentralCrossRef Ohno T, Adachi S, Okuno M, et al. Development of a novel scoring system for predicting the risk of colorectal neoplasia: a retrospective study. PLoS ONE. 2016;11:e0157269.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Szylberg L, Janiczek M, Popiel A, et al. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract. 2015;2015:573814.PubMedPubMedCentralCrossRef Szylberg L, Janiczek M, Popiel A, et al. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract. 2015;2015:573814.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Cebola I, Custodio J, Munoz M, et al. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics. 2015;7:74.PubMedPubMedCentralCrossRef Cebola I, Custodio J, Munoz M, et al. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics. 2015;7:74.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Li W, Qiu T, Ling Y, et al. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget. 2015;6:39607–13.PubMedPubMedCentral Li W, Qiu T, Ling Y, et al. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget. 2015;6:39607–13.PubMedPubMedCentral
22.
Zurück zum Zitat Tillmans LS, Vierkant RA, Wang AH, et al. Associations between environmental exposures and incident colorectal cancer by ESR2 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev. 2015;24:713–9.PubMedPubMedCentralCrossRef Tillmans LS, Vierkant RA, Wang AH, et al. Associations between environmental exposures and incident colorectal cancer by ESR2 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev. 2015;24:713–9.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Mehta AM, Osse M, Kolkman-Uljee S, et al. Molecular backgrounds of ERAP1 downregulation in cervical carcinoma. Anal Cell Pathol (Amst). 2015;2015:367837.PubMedPubMedCentral Mehta AM, Osse M, Kolkman-Uljee S, et al. Molecular backgrounds of ERAP1 downregulation in cervical carcinoma. Anal Cell Pathol (Amst). 2015;2015:367837.PubMedPubMedCentral
24.
Zurück zum Zitat Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20:6055–72.PubMedPubMedCentralCrossRef Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20:6055–72.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23:2694–702.PubMedCrossRef Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23:2694–702.PubMedCrossRef
26.
Zurück zum Zitat Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30:12–25.PubMedCrossRef Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30:12–25.PubMedCrossRef
27.
Zurück zum Zitat Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p. V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev. 2013;22:917–26.PubMedPubMedCentralCrossRef Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p. V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev. 2013;22:917–26.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9:561–70.PubMedCrossRef Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9:561–70.PubMedCrossRef
29.
Zurück zum Zitat Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012;1825:77–85.PubMed Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012;1825:77–85.PubMed
30.
Zurück zum Zitat Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674.PubMedPubMedCentral Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674.PubMedPubMedCentral
32.
Zurück zum Zitat Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies-the key to unlocking precision medicine. N Engl J Med. 2016;375:4–6.PubMedCrossRef Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies-the key to unlocking precision medicine. N Engl J Med. 2016;375:4–6.PubMedCrossRef
33.
Zurück zum Zitat Kuller LH, Bracken MB, Ogino S, et al. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178:1350–4.PubMedPubMedCentralCrossRef Kuller LH, Bracken MB, Ogino S, et al. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178:1350–4.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: an ASPO molecular epidemiology and the environment and international cancer prevention interest groups report. Cancer Epidemiol Biomarkers Prev. 2014;23:2613–7.PubMedPubMedCentralCrossRef Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: an ASPO molecular epidemiology and the environment and international cancer prevention interest groups report. Cancer Epidemiol Biomarkers Prev. 2014;23:2613–7.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Ogino S. Molecular pathological epidemiology (MPE): overview of its paradigm and wide applicability even without tumor tissue [abstract]. In: Proceedings of the twelfth annual AACR international conference on frontiers in cancer prevention research; 2013 Oct 27–30. National Harbor, MD: Cancer Prev Res (Phila); 2013;6:CN06-01. Ogino S. Molecular pathological epidemiology (MPE): overview of its paradigm and wide applicability even without tumor tissue [abstract]. In: Proceedings of the twelfth annual AACR international conference on frontiers in cancer prevention research; 2013 Oct 27–30. National Harbor, MD: Cancer Prev Res (Phila); 2013;6:CN06-01.
36.
Zurück zum Zitat Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26:959–72.PubMedPubMedCentralCrossRef Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26:959–72.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Nishi A, Milner DA Jr, Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016;16:11–23.PubMedCrossRef Nishi A, Milner DA Jr, Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016;16:11–23.PubMedCrossRef
38.
39.
Zurück zum Zitat Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRef Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRef
40.
Zurück zum Zitat Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(77–87):e2. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(77–87):e2.
42.
43.
Zurück zum Zitat Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(1244–60):e16. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(1244–60):e16.
44.
46.
Zurück zum Zitat Aran V, Victorino AP, Thuler LC, et al. Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Clin Colorectal Cancer. 2016. Aran V, Victorino AP, Thuler LC, et al. Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Clin Colorectal Cancer. 2016.
47.
Zurück zum Zitat Lochhead P, Chan AT, Giovannucci E, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014;109:1205–14.PubMedPubMedCentralCrossRef Lochhead P, Chan AT, Giovannucci E, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014;109:1205–14.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310:2147–8.PubMedCrossRef Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310:2147–8.PubMedCrossRef
49.
Zurück zum Zitat Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA. 2013;310:2401–2.PubMedCrossRef Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA. 2013;310:2401–2.PubMedCrossRef
50.
Zurück zum Zitat Reddon H, Gueant JL, Meyre D. The importance of gene-environment interactions in human obesity. Clin Sci (Lond). 2016;130:1571–97.PubMedCrossRef Reddon H, Gueant JL, Meyre D. The importance of gene-environment interactions in human obesity. Clin Sci (Lond). 2016;130:1571–97.PubMedCrossRef
51.
Zurück zum Zitat Bam M, Yang X, Zumbrun EE, et al. Dysregulated immune system networks in war veterans with PTSD is an outcome of altered miRNA expression and DNA methylation. Sci Rep. 2016;6:31209.PubMedPubMedCentralCrossRef Bam M, Yang X, Zumbrun EE, et al. Dysregulated immune system networks in war veterans with PTSD is an outcome of altered miRNA expression and DNA methylation. Sci Rep. 2016;6:31209.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–42.PubMedCrossRef Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–42.PubMedCrossRef
54.
55.
Zurück zum Zitat Yamauchi M, Lochhead P, Imamura Y, et al. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1142–52.PubMedPubMedCentralCrossRef Yamauchi M, Lochhead P, Imamura Y, et al. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1142–52.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309:2563–71.PubMedPubMedCentralCrossRef Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309:2563–71.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178:84–100.PubMedPubMedCentralCrossRef Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178:84–100.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Hanyuda A, Kim SA, Martinez-Fernandez A, et al. Survival benefit of exercise differs by tumor IRS1 expression status in colorectal cancer. Ann Surg Oncol. 2016;23:908–17.PubMedCrossRef Hanyuda A, Kim SA, Martinez-Fernandez A, et al. Survival benefit of exercise differs by tumor IRS1 expression status in colorectal cancer. Ann Surg Oncol. 2016;23:908–17.PubMedCrossRef
59.
Zurück zum Zitat Frampton M, Houlston RS. Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. Genet Med. 2016. Frampton M, Houlston RS. Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. Genet Med. 2016.
60.
Zurück zum Zitat Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res. 2013;73:1600–10.PubMedPubMedCentralCrossRef Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res. 2013;73:1600–10.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275:1784–7.PubMedCrossRef Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275:1784–7.PubMedCrossRef
62.
Zurück zum Zitat Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305:1685–94.PubMedPubMedCentralCrossRef Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305:1685–94.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Ogino S, Galon J, Fuchs CS, et al. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711–9.PubMedPubMedCentralCrossRef Ogino S, Galon J, Fuchs CS, et al. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711–9.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–54.PubMedPubMedCentralCrossRef Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–54.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6:233re2. Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6:233re2.
67.
Zurück zum Zitat Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4:1808–15.PubMedPubMedCentralCrossRef Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4:1808–15.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103:1540–51.PubMedPubMedCentralCrossRef Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103:1540–51.PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31:4297–305.PubMedCrossRef Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31:4297–305.PubMedCrossRef
70.
71.
Zurück zum Zitat Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16:173–86.PubMedCrossRef Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16:173–86.PubMedCrossRef
72.
Zurück zum Zitat Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50.PubMedCrossRef Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50.PubMedCrossRef
73.
Zurück zum Zitat Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601.PubMedCrossRef Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601.PubMedCrossRef
74.
Zurück zum Zitat Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64:1419–25.PubMedCrossRef Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64:1419–25.PubMedCrossRef
75.
Zurück zum Zitat Friis S, Riis AH, Erichsen R, et al. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based. case-control study. Ann Intern Med. 2015;163:347–55.PubMedCrossRef Friis S, Riis AH, Erichsen R, et al. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based. case-control study. Ann Intern Med. 2015;163:347–55.PubMedCrossRef
76.
Zurück zum Zitat Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836–45.PubMedCrossRef Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836–45.PubMedCrossRef
77.
Zurück zum Zitat Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016. Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016.
78.
Zurück zum Zitat Garcia-Albeniz X, Nan H, Valeri L, et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis. 2013;34:292–8.PubMedCrossRef Garcia-Albeniz X, Nan H, Valeri L, et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis. 2013;34:292–8.PubMedCrossRef
79.
Zurück zum Zitat Nan H, Hutter CM, Lin Y, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313:1133–42.PubMedPubMedCentralCrossRef Nan H, Hutter CM, Lin Y, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313:1133–42.PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852–61.PubMedPubMedCentralCrossRef Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852–61.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Khalili H, Gong J, Brenner H, et al. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis. 2015;36:999–1007.PubMedPubMedCentralCrossRef Khalili H, Gong J, Brenner H, et al. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis. 2015;36:999–1007.PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Garcia-Albeniz X, Rudolph A, Hutter C, et al. CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer. 2016;114:221–9.PubMedPubMedCentralCrossRef Garcia-Albeniz X, Rudolph A, Hutter C, et al. CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer. 2016;114:221–9.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.PubMedCrossRef Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.PubMedCrossRef
84.
Zurück zum Zitat Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.PubMedCrossRef Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.PubMedCrossRef
85.
Zurück zum Zitat Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15:6412–20.PubMedPubMedCentralCrossRef Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15:6412–20.PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.PubMedPubMedCentralCrossRef Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.PubMedPubMedCentralCrossRef
87.
89.
Zurück zum Zitat Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–73.PubMedCrossRef Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–73.PubMedCrossRef
90.
92.
Zurück zum Zitat Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol. 2016;43:161–72.PubMedCrossRef Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol. 2016;43:161–72.PubMedCrossRef
94.
Zurück zum Zitat Janakiram NB, Mohammed A, Madka V, et al. Prevention and treatment of cancers by immune modulating nutrients. Mol Nutr Food Res. 2016;60:1275–94.PubMedCrossRef Janakiram NB, Mohammed A, Madka V, et al. Prevention and treatment of cancers by immune modulating nutrients. Mol Nutr Food Res. 2016;60:1275–94.PubMedCrossRef
95.
Zurück zum Zitat Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.PubMedCrossRef Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.PubMedCrossRef
96.
Zurück zum Zitat Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.PubMedPubMedCentralCrossRef Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106:dju294. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106:dju294.
98.
99.
Zurück zum Zitat Hussain M, Javeed A, Ashraf M, et al. Aspirin and immune system. Int Immunopharmacol. 2012;12:10–20.PubMedCrossRef Hussain M, Javeed A, Ashraf M, et al. Aspirin and immune system. Int Immunopharmacol. 2012;12:10–20.PubMedCrossRef
100.
Zurück zum Zitat Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2016. Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2016.
101.
Zurück zum Zitat Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.PubMedPubMedCentralCrossRef Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.PubMedPubMedCentralCrossRef Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.PubMedCrossRef Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.PubMedCrossRef
104.
Zurück zum Zitat Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.PubMedCrossRef Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.PubMedCrossRef
105.
Zurück zum Zitat Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842–57.PubMedCrossRef Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842–57.PubMedCrossRef
106.
Zurück zum Zitat Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2016;65:296–304.PubMedCrossRef Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2016;65:296–304.PubMedCrossRef
107.
Zurück zum Zitat Song M, Nishihara R, Cao Y, et al. Marine omega-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol. 2016. Song M, Nishihara R, Cao Y, et al. Marine omega-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol. 2016.
108.
Zurück zum Zitat Hanyuda A, Ogino S, Qian ZR, et al. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer. 2016;139:854–68.PubMedCrossRef Hanyuda A, Ogino S, Qian ZR, et al. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer. 2016;139:854–68.PubMedCrossRef
109.
Zurück zum Zitat Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–20.PubMedCrossRef Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–20.PubMedCrossRef
110.
111.
Zurück zum Zitat Amirian ES, Petrosino JF, Ajami NJ, et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer. 2013;8:42.PubMedPubMedCentralCrossRef Amirian ES, Petrosino JF, Ajami NJ, et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer. 2013;8:42.PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Claassen-Weitz S, Wiysonge CS, Machingaidze S, et al. Current knowledge and future research directions on fecal bacterial patterns and their association with asthma. Front Microbiol. 2016;7:838.PubMedPubMedCentral Claassen-Weitz S, Wiysonge CS, Machingaidze S, et al. Current knowledge and future research directions on fecal bacterial patterns and their association with asthma. Front Microbiol. 2016;7:838.PubMedPubMedCentral
114.
Zurück zum Zitat Flemer B, Lynch DB, Brown JM, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2016. Flemer B, Lynch DB, Brown JM, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2016.
115.
Zurück zum Zitat Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.PubMedPubMedCentralCrossRef Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.PubMedPubMedCentralCrossRef
116.
Zurück zum Zitat Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.PubMedPubMedCentralCrossRef Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.PubMedPubMedCentralCrossRef
117.
Zurück zum Zitat Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2015. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2015.
119.
Zurück zum Zitat Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74:1311–8.PubMedPubMedCentralCrossRef Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74:1311–8.PubMedPubMedCentralCrossRef
120.
Zurück zum Zitat Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–68.PubMedCrossRef Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–68.PubMedCrossRef
121.
122.
Zurück zum Zitat Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9.PubMedPubMedCentralCrossRef Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9.PubMedPubMedCentralCrossRef
123.
Zurück zum Zitat Desai NB, Scott SN, Zabor EC, et al. Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016. Desai NB, Scott SN, Zabor EC, et al. Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016.
124.
Zurück zum Zitat Dixon SC, Nagle CM, Thrift AP, et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016. Dixon SC, Nagle CM, Thrift AP, et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016.
125.
Zurück zum Zitat Mima K, Nishihara R, Yang J, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016;22:3841–8.PubMedCrossRef Mima K, Nishihara R, Yang J, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016;22:3841–8.PubMedCrossRef
126.
Zurück zum Zitat Sisti JS, Collins LC, Beck AH, et al. Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses’ health studies. Int J Cancer. 2016;138:2346–56.PubMedCrossRef Sisti JS, Collins LC, Beck AH, et al. Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses’ health studies. Int J Cancer. 2016;138:2346–56.PubMedCrossRef
127.
Zurück zum Zitat Mima K, Nowak JA, Qian ZR, et al. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016. Mima K, Nowak JA, Qian ZR, et al. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016.
128.
Zurück zum Zitat Hirko KA, Willett WC, Hankinson SE, et al. Healthy dietary patterns and risk of breast cancer by molecular subtype. Breast Cancer Res Treat. 2016;155:579–88.PubMedPubMedCentralCrossRef Hirko KA, Willett WC, Hankinson SE, et al. Healthy dietary patterns and risk of breast cancer by molecular subtype. Breast Cancer Res Treat. 2016;155:579–88.PubMedPubMedCentralCrossRef
129.
Zurück zum Zitat Simons CC, Schouten LJ, Godschalk R, et al. Body size, physical activity, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Carcinogenesis. 2015;36:971–81.PubMedCrossRef Simons CC, Schouten LJ, Godschalk R, et al. Body size, physical activity, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Carcinogenesis. 2015;36:971–81.PubMedCrossRef
130.
Zurück zum Zitat Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24:1229–38.PubMedPubMedCentralCrossRef Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24:1229–38.PubMedPubMedCentralCrossRef
131.
Zurück zum Zitat Hardikar S, Newcomb PA, Campbell PT, et al. Prediagnostic physical activity and colorectal cancer survival: overall and stratified by tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2015;24:1130–7.PubMedPubMedCentralCrossRef Hardikar S, Newcomb PA, Campbell PT, et al. Prediagnostic physical activity and colorectal cancer survival: overall and stratified by tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2015;24:1130–7.PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Simons CC, van den Brandt PA, Stehouwer CD, et al. Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:1852–62.PubMedCrossRef Simons CC, van den Brandt PA, Stehouwer CD, et al. Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:1852–62.PubMedCrossRef
133.
Zurück zum Zitat Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110:1359–66.PubMedPubMedCentralCrossRef Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110:1359–66.PubMedPubMedCentralCrossRef
134.
Zurück zum Zitat Brandstedt J, Wangefjord S, Nodin B, et al. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.PubMedPubMedCentralCrossRef Brandstedt J, Wangefjord S, Nodin B, et al. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.PubMedPubMedCentralCrossRef
135.
Zurück zum Zitat Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.PubMedCrossRef Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.PubMedCrossRef
136.
Zurück zum Zitat Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109:1004–12.PubMedPubMedCentralCrossRef Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109:1004–12.PubMedPubMedCentralCrossRef
137.
Zurück zum Zitat Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060–72.PubMedCrossRef Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060–72.PubMedCrossRef
138.
Zurück zum Zitat Cao Y, Nishihara R, Qian ZR, et al. Regular Aspirin Use Associates with Lower Risk of Colorectal Cancers With Low Numbers of Tumor-infiltrating Lymphocytes. Gastroenterology. 2016. Cao Y, Nishihara R, Qian ZR, et al. Regular Aspirin Use Associates with Lower Risk of Colorectal Cancers With Low Numbers of Tumor-infiltrating Lymphocytes. Gastroenterology. 2016.
140.
Zurück zum Zitat Rogers MA, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22(178):e1–9. Rogers MA, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22(178):e1–9.
141.
Zurück zum Zitat Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178:296–308.PubMedPubMedCentralCrossRef Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178:296–308.PubMedPubMedCentralCrossRef
142.
Zurück zum Zitat Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med. 2015;4:1432–9.PubMedPubMedCentralCrossRef Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med. 2015;4:1432–9.PubMedPubMedCentralCrossRef
143.
Zurück zum Zitat Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol. 2015;182:263–70.PubMedPubMedCentralCrossRef Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol. 2015;182:263–70.PubMedPubMedCentralCrossRef
144.
Zurück zum Zitat Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35:782–800.PubMedCrossRef Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35:782–800.PubMedCrossRef
145.
Zurück zum Zitat Mauguen A, Begg CB. Using the Lorenz curve to characterize risk predictiveness and etiologic heterogeneity. Epidemiology. 2016;27:531–7.PubMedCrossRef Mauguen A, Begg CB. Using the Lorenz curve to characterize risk predictiveness and etiologic heterogeneity. Epidemiology. 2016;27:531–7.PubMedCrossRef
146.
Zurück zum Zitat Begg CB, Seshan VE, Zabor EC, et al. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014;14:138.PubMedPubMedCentralCrossRef Begg CB, Seshan VE, Zabor EC, et al. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014;14:138.PubMedPubMedCentralCrossRef
147.
Zurück zum Zitat Chatterjee N, Sinha S, Diver WR, et al. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika. 2010;97:683–98.PubMedPubMedCentralCrossRef Chatterjee N, Sinha S, Diver WR, et al. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika. 2010;97:683–98.PubMedPubMedCentralCrossRef
148.
Zurück zum Zitat Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol. 2012;176:659–67.PubMedPubMedCentralCrossRef Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol. 2012;176:659–67.PubMedPubMedCentralCrossRef
149.
Zurück zum Zitat Kuller LH. Invited commentary: the 21st century epidemiologist—a need for different training? Am J Epidemiol. 2012;176:668–71.PubMedCrossRef Kuller LH. Invited commentary: the 21st century epidemiologist—a need for different training? Am J Epidemiol. 2012;176:668–71.PubMedCrossRef
150.
151.
Zurück zum Zitat Ogino S, Nishihara R. All biomedical and health science researchers, including laboratory physicians and scientists, need adequate education and training in study design and statistics. Clin Chem. 2016;62:1039–40.PubMedCrossRef Ogino S, Nishihara R. All biomedical and health science researchers, including laboratory physicians and scientists, need adequate education and training in study design and statistics. Clin Chem. 2016;62:1039–40.PubMedCrossRef
Metadaten
Titel
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis
verfasst von
Tsuyoshi Hamada
NaNa Keum
Reiko Nishihara
Shuji Ogino
Publikationsdatum
13.10.2016
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 3/2017
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1272-3

Weitere Artikel der Ausgabe 3/2017

Journal of Gastroenterology 3/2017 Zur Ausgabe

Acknowledgment

Acknowledgments

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.